华芢生物-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02396 华芢生物-B

待上市 12-12 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本1.18亿
成交额0.00	换手率0.00%	流通股本8,302万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02396","market":"HK","secType":"STK","nameCN":"华芢生物-B","latestPrice":0,"timestamp":1765526400000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":83022145,"shares":117657522,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-12 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":8,"adr":0,"listingDate":1766332800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0,"ipoDetail":{"name":"华芢生物－Ｂ","exchange":"SEHK","listingDate":"2025-12-22","sharesOutstanding":117657522,"sharesFloat":117657522,"offerAmount":17648800,"priceRange":"38.200 - 51.000","market":"HK","openProspectusDate":"2025-12-12","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1212/2025121200082_c.pdf","purchaseBeginDate":"2025-12-12","purchaseEndDate":"2025-12-17","winningDate":"2025-12-19","currency":"HKD","minPurchaseQuantity":200,"peRate":-23.18,"use":"1、约61.8%或437.6百万港元，将用于资助公司核心产品Pro101-1及Pro-101-2的持续临床开发及商业化；\n2、约18.8%或133.5百万港元，将用于通过购买与研发及质量控制活动相关的专业设备及仪器来提升公司研发能力；\n3、约6.3%或44.5百万港元，将用于支付公司核心产品以外的PDGF产品用于治疗其他适应症的持续临床前研发的第三方服务费、研发人员费用及原材料成本；\n4、约3.1%或22.3百万港元，将用于支付Mes-201、Oli-101及Oli201临床前研发活动的第三方服务费、研发人员费用及原材料成本；\n5、约10.0%或70.9百万港元，用作营运资金及一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物，主攻方向是发现、开发和商业化伤口愈合的疗法，目前为PDGF药物。","subscribed":74.28,"marketCap":4495000000,"minimumCapital":10302.88,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,500000,600000,700000,882400"},"greyMarketDetail":{"greyDate":"2025-12-19","greyDateTimestamp":1766073600000,"greyOpeningTime":1766132100000,"greyClosingTime":1766140200000,"showGreyQuote":false,"openProspectusDate":"2025-12-12","listingDate":"2025-12-22"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02396","defaultTab":"news","newsList":[{"id":"2590573465","title":"华芢生物上市进程稳步推进 稀缺PDGF管线填补糖足治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2590573465","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590573465?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:06","pubTimestamp":1765523182,"startTime":"0","endTime":"0","summary":"本报讯（记者袁传玺）12月12日，专注于伤口愈合多功能疗法的创新药企华芢生物科技（青岛）股份有限公司（以下简称“华芢生物”）上市进程正顺利推进，公司相关上市筹备工作已进入关键阶段，其稀缺的PDGF药物管线及广阔的市场前景引发行业广泛关注。据悉，华芢生物成立于2012年，已布局十款候选产品、覆盖14种创面愈合适应症，核心产品矩阵具备显著竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590099089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02396"],"gpt_icon":0},{"id":"2590284225","title":"【新股IPO】华芢生物-B(02396)今日起招股 入场费10302.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590284225","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590284225?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:48","pubTimestamp":1765500493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华生物-B 今日起招股，拟发行1764.88万股H股，其中10%为香港发售，90%为国际发售，另有15%超额配股权。每股招股价介于38.2港元至51港元，每手200股，入场费10302.88港元。股份预期将于2025年12月22日挂牌上市，华泰国际、中信证券为联席保荐人。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NGRkYjNjMjA4MTA4NTEzNjUxMTI4.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NGRkYjNjMjA4MTA4NTEzNjUxMTI4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971413","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"gpt_icon":0},{"id":"1125318237","title":"新股招股｜华芢生物-B今日起招股，一手入场费10302.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125318237","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125318237?lang=zh_cn&edition=full","pubTime":"2025-12-12 07:35","pubTimestamp":1765496151,"startTime":"0","endTime":"0","summary":"12月12日，华生物-B于12月12日-12月17日招股，公司拟全球发售1764.88万股H股，其中，香港公开发售占约10%，国家发售占约90%，另有15%超额配股权。申购阶梯：每手200股，入场费10302.88港元。于往绩记录期间，集团并无盈利并产生净亏损。于2023年、2024年以及截至2024年及2025年9月30日止九个月，集团的净亏损分别为人民币1.05亿元、人民币2.12亿元、人民币1.64亿元及人民币1.35亿元。集团绝大部分的净亏损乃由研发费用及行政开支导致。","market":"hk","thumbnail":"https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜华芢生物-B今日起招股，一手入场费10302.88港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"gpt_icon":1},{"id":"2590301534","title":"新股消息 | 华芢生物通过港交所聆讯 仅有两款核心产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2590301534","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590301534?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:36","pubTimestamp":1765352169,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月10日披露，华生物科技(青岛)股份有限公司-B通过港交所主板上市聆讯，华泰国际、中信证券为联席保荐人。该公司亦有八款其他候选产品。该公司或许不能成功开发及╱或推广该公司的核心产品。该公司仅有两款核心产品，即Pro-101-1及Pro-101-2。该公司预期，一旦该公司的PDGF候选产品实现商业化，其主要市场将在中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02396","HEXmain"],"gpt_icon":0},{"id":"2590742372","title":"华芢生物科技（青岛）股份有限公司- B已递交聆讯后资料集","url":"https://stock-news.laohu8.com/highlight/detail?id=2590742372","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590742372?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:40","pubTimestamp":1765338001,"startTime":"0","endTime":"0","summary":"览富财经网讯：12月10日，港交所官网显示，华芢生物科技(青岛)股份有限公司 - B(简称：华芢生物)已递交聆讯后资料集，登陆香港联合交易所主板指日可待。    据了解，华芢生物成立于2012年，是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。公司的主攻方向是发现、开 发和商业化伤口愈合的疗法，目前为PDGF药物。截至最后实际可行日期，我华芢生物的管线包含十款候选产品，其中七款为PDGF候选药物，包括两款核心产品，即用于治疗烧烫 伤的Pro-101-1及用于治疗糖足的Pro-101-2，是rhPDGF-BB药物。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/10/20251210969933.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/10/20251210969933.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31855721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02396","159837"],"gpt_icon":0},{"id":"2560977093","title":"【新股IPO】华芢生物再度递表港交所 料2025年净亏损将大幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2560977093","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560977093?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:25","pubTimestamp":1755505537,"startTime":"0","endTime":"0","summary":"华生物于2024年12月27日已通过中国证监会IPO备案，拿到了上市钥匙。截至同日，在中国尚无获批的PDGF药物。另外两条PDGF-BB管线属于华生物，已分别于2022年2月进入治疗糖足的II期临床试验及于2025年4月完成治疗烧烫伤的IIb期临床试验。值得注意的是，公司预计截至2025年12月31日止年度净亏损将大幅增加，主要因为公司继续推进候选药物研发预期将产生重大研发费用，而公司预期2025年不会自候选药物商业化获得可观收入。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NjVlYjQ4Njc4MjEwMjU5Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjVlYjQ4Njc4MjEwMjU5Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1964285","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","02396"],"gpt_icon":0},{"id":"2560924380","title":"新股消息 | 华芢生物三度递表港交所 用于治疗烧烫伤的Pro-101-1已在中国完成IIb期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2560924380","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560924380?lang=zh_cn&edition=full","pubTime":"2025-08-17 16:24","pubTimestamp":1755419063,"startTime":"0","endTime":"0","summary":"截至最后实际可行日期，公司用于治疗烧烫伤的Pro-101-1已在中国完成IIb期临床试验，并正处于确定临床试验报告的阶段；且公司用于治疗糖足的Pro-101-2正在中国进行II期临床试验。此外，公司计划在美国推出Pro-101-1。PDGF是唯一获FDA批准用于外用的重组生长因子，特别是用于治疗糖足。预计临床开发完成后，公司将成为Pro-101-2MAH许可的唯一持有人。据董事所知，军科院并未在项目内外从事任何有关PDGF用于治疗糖足的研发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","02396"],"gpt_icon":0},{"id":"2560804921","title":"华芢生物冲刺港股：年亏损2亿 估值33亿 已获IPO备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2560804921","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560804921?lang=zh_cn&edition=full","pubTime":"2025-08-17 09:55","pubTimestamp":1755395744,"startTime":"0","endTime":"0","summary":"华芢生物科技（青岛）股份有限公司（简称：“华芢生物”）日前更新招股书，准备在港交所上市。招股书显示，华芢生物2023年、2024年营收分别为47.2万元、26.1万元；年内亏损分别为1.05亿元、2.12亿元；","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250817/6389102132780174079524647.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250817/6389102132780174079524647.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n30846/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["YANG","BK4614","02396","HSCEI","HSTECH"],"gpt_icon":1},{"id":"2559910124","title":"【新股IPO】华芢生物科技(青岛)股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2559910124","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559910124?lang=zh_cn&edition=full","pubTime":"2025-08-15 23:42","pubTimestamp":1755272565,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所8月15日披露，华生物科技 股份有限公司向港交所主板提交上市申请，华泰国际和中信证券为联席保荐人。公司成立于2012年，是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。公司的主攻方向是发现、开发和商业化伤口愈合的疗法，目前为血小板衍生生长因子药物。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MWMzMWU4NjgxMDkxMjQ0ODA=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWMzMWU4NjgxMDkxMjQ0ODA=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1964205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396","159837","HEXmain"],"gpt_icon":0},{"id":"2547054609","title":"港交所，已成青岛企业上市首要选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2547054609","media":"青岛创客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547054609?lang=zh_cn&edition=full","pubTime":"2025-06-30 14:36","pubTimestamp":1751265380,"startTime":"0","endTime":"0","summary":"“去香港上市”，正成为青岛企业界的热词。6月26日，青岛国恩科技股份有限公司向港交所主板提交上市申请，这是继歌尔微、文达通、圣桐特医、酷特智能之后，青岛今年第5家赴港上市的企业。4月3日，青岛文达通科技股份有限公司向港交所主板递交上市申请。推进全球化战略全球化战略亦是青岛企业筹划赴港上市的一大原因。可以预见，青岛企业去香港上市的这波热度有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143913a72562d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143913a72562d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["80388","02497","BK1212","02396","00388","BK1131"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huarenshengwu.com","compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"我们成立于2012年,是一家总部位于中国的生物制药公司,致力于开发疗法,重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。我们的主攻方向是发现、开发和商业化伤口愈合的疗法,目前为PDGF药物。截至最后实际可行日期,我们的管线包含十款候选产品,其中七款为PDGF候选药物,包括两款核心产品,即用于治疗烧烫伤的Pro-101-1及用于治疗糖足的Pro-101-2,是rhPDGF-BB药物。","exchange":"SEHK","name":"华芢生物-B","nameEN":"B&K CORP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华芢生物-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华芢生物-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华芢生物-B,02396,华芢生物-B股票,华芢生物-B股票老虎,华芢生物-B股票老虎国际,华芢生物-B行情,华芢生物-B股票行情,华芢生物-B股价,华芢生物-B股市,华芢生物-B股票价格,华芢生物-B股票交易,华芢生物-B股票购买,华芢生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华芢生物-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华芢生物-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}